US Supreme Court Won’t Review Bayer AG, Teva Pharmaceutical Industries Limited Drug Patent Deal

March 8, 2011 |

1 min read

(Reuters) - The U.S. Supreme Court declined on Monday to review whether patent settlements by drug companies that pay rivals to delay production of generic drugs violate federal antitrust law.

Legal

MORE ON THIS TOPIC

Recovering losses, effective economic measures to help alleviate inflation or economic crisis resulting in the collapse of the business economy or stock market, helping hands to catch gold coins rolling down a tilted cliff

Patents

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

April 29, 2026

·

2 min read

·

Nick Paul Taylor

man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top

Pancreatic cancer

Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up

April 28, 2026

·

3 min read

·

Tristan Manalac

Stack of coins balancing on seesaw over a bottle of pills.

Drug pricing

Regeneron finally joins Trump’s drug pricing push while notching landmark approval

April 24, 2026

·

2 min read

·

Tristan Manalac

Composite photo collage of hands hold picket poster riot agitation strike crowd people democracy solidarity isolated on painted background.

Complete response letters

Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters

April 23, 2026

·

2 min read

·

Tristan Manalac